ADA	Adalimumab
AS	Ankylosing spondylitis
CD	Crohn’s disease
COPD	Chronic obstructive pulmonary disease
CTZ	Certolizumab
DMARD	Disease-modifying anti-rheumatic drug(s)
ETN	Etanercept
FAERS	[United States] Food and Drug Administration Adverse Events Reporting System
FDA	[United States] Food and Drug Administration
GBM	Glioblastoma multiforme
GLM	Golimumab
HL	Hodgkin’s Lymphoma(s)
HR	Hazard ratio(s)
HS	Hidradenitis suppurativa
INX	Infliximab
IQR	Interquartile range
IRB	Institutional Review Board
JIA	Juvenile idiopathic arthritis
MeSH	[National Library of Medicine] Medical subject heading(s)
MTX	Methotrexate
NHL	Non-Hodgkin’s Lymphoma(s)
NMSC	Non-melanoma skin cancer(s)
OA	Osteoarthritis
PS	Psoriasis
PSA	Psoriatic arthritis
RA	Rheumatoid arthritis
RR	Rate ratio(s)
SCC	Squamous cell carcinoma
SD	Standard deviation(s)
SPA	Spondyloarthropathy/spondyloarthropathies
SS	Sjogren’s syndrome
TNF-α	Tumor necrosis factor-alpha
TNF-i	Tumor necrosis factor-alpha inhibitor(s)
TNF-R	Tumor necrosis factor receptor
UC	Ulcerative colitis
95% CI	95% confidence interval